Mucosal IgG and IgA Responses to Human Papillomavirus Type 16 Capsid Proteins in HPV16-Infected Women without Visible Pathology
- 1 June 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Viral Immunology
- Vol. 16 (2) , 159-168
- https://doi.org/10.1089/088282403322017893
Abstract
Human papillomavirus type 16 (HPV16) may infect the cervical epithelium without producing pathological changes for a long time. To investigate if mucosal antibodies are induced in HPV16-infected women without visible pathology, cervical mucus from HPV16-infected patients with and without evident pathology, along with mucus from uninfected women were analyzed for the presence of mucosal IgG and secretory IgA (sIgA) antibodies to HPV16 capsid proteins by ELISA. sIgA and IgG antibodies were found in a significantly higher proportion of infected patients compared with uninfected women (p < 0.0001). sIgA antibodies were present in 13.1% of infected patients without visible pathology, the proportion of positivity increased to 27.0% in patients with visible pathology (p = 0.001). Mucosal IgG response was observed in 6.5% of patients without and 27.5% of patients with visible pathology (p = 0.00005). The antibody mean signal strength was significantly higher in patients with than in patients without pathological evidence (p < 0.005). In conclusion, both sIgA and IgG are found in patients without pathological signs of infection, however, the response increases significantly in patients with pathological evidence, suggesting that the appearance of these changes might be associated with a more vigorous antibody-mediated mucosal reaction.Keywords
This publication has 37 references indexed in Scilit:
- Antibodies against Human Papillomavirus Type 16 and 18 E6 and E7 Proteins in Cervicovaginal Washings and Serum of Patients with Cervical NeoplasiaViral Immunology, 2001
- Oral antibodies to human papillomavirus type 16 in women with cervical neoplasiaJournal of Medical Virology, 2001
- Cervical secretory immunoglobulin A to human papillomavirus type 16 (HPV16) from HPV16-infected women inhibit HPV16 virus-like particles-induced hemagglutination of mouse red blood cellsFEMS Immunology & Medical Microbiology, 2001
- Type Specificity and Significance of Different Isotypes of Serum Antibodies to Human Papillomavirus CapsidsThe Journal of Infectious Diseases, 2000
- Seroreactivity to Human Papillomavirus Types 16, 18, 31, and 45 Virus‐Like Particles in a Case‐Control Study of Cervical Squamous Intraepithelial LesionsThe Journal of Infectious Diseases, 1999
- Presence of antibodies to human papillomavirus virus‐like particles (VLPs) in 11–13‐year‐old schoolgirlsJournal of Medical Virology, 1998
- Immunoglobulin‐A and ‐G responses against virus‐like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra‐epithelial lesionsInternational Journal of Cancer, 1998
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Human papillomavirus DNA and anti‐HPV secretory IgA antibodies in cytologically normal cervical specimensJournal of Medical Virology, 1994
- Detection of Human Papillomavirus L1 Protein in Condylomata Acuminata From Various Anatomical SitesSexually Transmitted Diseases, 1994